About

A-Alpha Bio leverages synthetic biology and machine learning to measure, understand, and engineer protein-protein interactions.

We partner with leading pharmaceutical companies to improve human health by unlocking the potential of protein-protein interactions.

Our platform, AlphaSeq, represents the first high-throughput and quantitative approach for measuring protein-protein binding. AlphaSeq generates the high-resolution data needed to discover rare and effective antibodies, identify degradable neo-substrates for molecular glues, redesign protein-protein interfaces for cell therapies, and fuel machine-learning models to further accelerate the discovery and optimization of high-impact drugs.

A-Alpha Bio was founded in 2017 as a spinout from the University of Washington’s Institute for Protein Design and Center for Synthetic Biology.